T E Wilens

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Atten Disord 5:189-202. 2002
  2. ncbi Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 24:36-41. 2004
  3. ncbi Attention deficit/hyperactivity disorder across the lifespan
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, 15 Parkman Street, Boston, Massachusetts 02114, USA
    Annu Rev Med 53:113-31. 2002
  4. ncbi Patterns of psychopathology and dysfunction in clinically referred preschoolers
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Dev Behav Pediatr 23:S31-6. 2002
  5. ncbi A family study of the high-risk children of opioid- and alcohol-dependent parents
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston 02114, USA
    Am J Addict 11:41-51. 2002
  6. ncbi Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Am Acad Child Adolesc Psychiatry 41:262-8. 2002
  7. ncbi A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors
    Timothy E Wilens
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Child Adolesc Psychopharmacol 13:143-52. 2003
  8. ncbi Drug therapy for adults with attention-deficit hyperactivity disorder
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Drugs 63:2395-411. 2003
  9. ncbi Fluoxetine pharmacokinetics in pediatric patients
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Clin Psychopharmacol 22:568-75. 2002
  10. ncbi Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Pediatrics 111:179-85. 2003

Detail Information

Publications75

  1. ncbi A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Atten Disord 5:189-202. 2002
    ..Despite the increasing recognition of attention deficit hyperactivity disorder (ADHD) in adults, the use of pharmacotherapeutics remains less established...
  2. ncbi Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 24:36-41. 2004
    ..We evaluated the longer-term effects on vital signs of once-daily osmotic-release methylphenidate (MPH, Concerta) in children with ADHD...
  3. ncbi Attention deficit/hyperactivity disorder across the lifespan
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, 15 Parkman Street, Boston, Massachusetts 02114, USA
    Annu Rev Med 53:113-31. 2002
    ..Pharmacotherapy, including stimulants, antidepressants, and antihypertensives, plays a fundamental role in the management of ADHD across the lifespan...
  4. ncbi Patterns of psychopathology and dysfunction in clinically referred preschoolers
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Dev Behav Pediatr 23:S31-6. 2002
    ..Preschoolers referred for psychiatric services had high rates of psychopathology with prominent comorbidity and associated dysfunction. These preschoolers are likely to require aggressive interventions including psychopharmacology...
  5. ncbi A family study of the high-risk children of opioid- and alcohol-dependent parents
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston 02114, USA
    Am J Addict 11:41-51. 2002
    ..With a growing consensus that certain risk factors for later SUD start in childhood with potentially treatable childhood-onset disorders, new preventive approaches for individuals at risk may be developed targeting childhood precursors of..
  6. ncbi Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Am Acad Child Adolesc Psychiatry 41:262-8. 2002
    ..We evaluated the clinical characteristics, psychiatric comorbidity, and functioning of preschool children and school-age youths with ADHD referred to a pediatric psychiatric clinic for evaluation...
  7. ncbi A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors
    Timothy E Wilens
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Child Adolesc Psychopharmacol 13:143-52. 2003
    ..To this end we completed a retrospective analysis of medical charts to determine the incidence, nature, and clinical correlates of treatment emergent adverse effects in the behavioral, cognitive, and emotional domains...
  8. ncbi Drug therapy for adults with attention-deficit hyperactivity disorder
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Drugs 63:2395-411. 2003
    ..Further studies are necessary to evaluate the long-term effectiveness and tolerability of various agents, functional and neuropsychological outcomes, and the use of various agents in specific subgroups of adults with ADHD...
  9. ncbi Fluoxetine pharmacokinetics in pediatric patients
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Clin Psychopharmacol 22:568-75. 2002
    ..The accumulation profile and steady-state concentrations in adolescents appear similar to those in adults...
  10. ncbi Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Pediatrics 111:179-85. 2003
    ..We investigated all long-term studies in which pharmacologically treated and untreated youths with ADHD were examined for later SUD outcomes...
  11. ncbi ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study
    Timothy Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, 15 Parkman Street, Boston, MA 02114, USA
    J Am Acad Child Adolesc Psychiatry 42:424-33. 2003
    ..This article reports an interim analysis of a 24-month study evaluating the 12-month tolerability and effectiveness of a once-daily OROS formulation of methylphenidate (OROS MPH) in children with ADHD...
  12. ncbi A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults
    T E Wilens
    Pediatric Psychopharmacology Clinic, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 158:282-8. 2001
    ..The authors report results from a controlled investigation to determine the anti-ADHD efficacy of bupropion in adult patients with DSM-IV ADHD...
  13. ncbi Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series
    T E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    J Child Adolesc Psychopharmacol 10:217-22. 2000
    ..We describe five cases of ADHD youths aged 8-17 years being treated for ADHD with the acetylcholinesterase inhibitor donepezil (Aricept), all of whom demonstrated improvement...
  14. ncbi A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder
    T E Wilens
    Pediatric Psychopharmacology Clinic, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Am J Psychiatry 156:1931-7. 1999
    ..Recent reports have suggested the potential usefulness of cholinergic agents for ADHD. To this end, the authors completed a controlled study of ABT-418, a novel cholinergic activating agent, for the treatment of adults with ADHD...
  15. ncbi Is bipolar disorder a risk for cigarette smoking in ADHD youth?
    T E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA
    Am J Addict 9:187-95. 2000
    ..These data coupled with the literature strongly suggest that juveniles with BPD need to be carefully monitored for the early initiation of cigarette smoking and substance abuse...
  16. ncbi The stimulants revisited
    T E Wilens
    Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
    Child Adolesc Psychiatr Clin N Am 9:573-603, viii. 2000
    ..Clinical guidelines for the management of individuals receiving the stimulants are offered, and treatment strategies delineated for ADHD subjects with comorbidity and medication-induced adverse effects are discussed...
  17. ncbi Clinical correlates of ADHD in females: findings from a large group of girls ascertained from pediatric and psychiatric referral sources
    J Biederman
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    J Am Acad Child Adolesc Psychiatry 38:966-75. 1999
    ..The aim of this study was to examine clinical correlates of ADHD in females using comprehensive assessments in multiple domains of functioning...
  18. ncbi Systematic chart review of the pharmacologic treatment of comorbid attention deficit hyperactivity disorder in youth with bipolar disorder
    J Biederman
    Pediatric Psychopharmacology Unit of the Child Psychiatry Service, Massachusetts General Hospital, Boston, USA
    J Child Adolesc Psychopharmacol 9:247-56. 1999
    ..Although TCAs can be helpful in the management of ADHD children with manic symptoms, these drugs should be used with caution since they can also have a destabilizing effect on manic symptoms...
  19. ncbi Parsing pediatric bipolar disorder from its associated comorbidity with the disruptive behavior disorders
    T J Spencer
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, Massachusetts 02114-3139, USA
    Biol Psychiatry 49:1062-70. 2001
    ..What was previously considered refractory ADHD, oppositionality, aggression, and conduct disorder may respond after mood stabilization. We review these issues in this article...
  20. ncbi Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young
    J Biederman
    Child Psychiatry Service, Massachusetts General Hospital, Boston, USA
    J Child Adolesc Psychopharmacol 10:185-92. 2000
    ..Because bipolar youth commonly come to clinical practice with depression, these results underscore the importance of assessing a lifetime history of bipolar disorder in making treatment decisions in depressed youth...
  21. ncbi The drug-placebo response curve: a new method for assessing drug effects in clinical trials
    S V Faraone
    The Pediatric Psychophamacology Unit of the Child Psychiatry Service, Massachusetts General Hospital, and Harvard Medical School, Boston 02114, USA
    J Clin Psychopharmacol 20:673-9. 2000
    ..The drug-placebo response curve provides clinically relevant information about the effect of drugs on continuous outcomes in controlled clinical trials...
  22. ncbi Risperidone treatment for juvenile bipolar disorder: a retrospective chart review
    J A Frazier
    Child Psychiatry Department, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    J Am Acad Child Adolesc Psychiatry 38:960-5. 1999
    ..To investigate the effectiveness and tolerability of the atypical neuroleptic risperidone in the treatment of juvenile mania...
  23. ncbi A naturalistic assessment of protriptyline for attention-deficit hyperactivity disorder
    T E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA
    J Am Acad Child Adolesc Psychiatry 35:1485-90. 1996
    ..To evaluate the potential benefit of the tricyclic antidepressant, protriptyline, in the treatment of children and adolescents with attention-deficit hyperactivity disorder (ADHD)...
  24. ncbi Neurocognitive impairment in unaffected siblings of youth with bipolar disorder
    A E Doyle
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Child Psychiatry Service, 55 Fruit Street, Boston, MA 02114, USA
    Psychol Med 39:1253-63. 2009
    ..The current study investigated whether these neurocognitive impairments index the familial risk underlying the diagnosis...
  25. ncbi Cigarette smoking associated with attention deficit hyperactivity disorder
    Timothy E Wilens
    Pediatric Psychopharmacology Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Pediatr 153:414-9. 2008
    ..To evaluate the association between attention deficit hyperactivity disorder (ADHD) and severity of physical dependence on nicotine in a controlled study of adolescents and young adults with ADHD...
  26. ncbi Impact of substance use disorder on ADHD and its treatment
    Timothy E Wilens
    Department of Pediatric Psychopharmacology, Massachusetts General Hospital, USA
    J Clin Psychiatry 68:e20. 2007
    ..SUD also complicates the diagnosis of adult ADHD. Fortunately, pharmacologic treatment of ADHD does not appear to increase the risk for development of SUD in ADHD patients...
  27. ncbi Familial transmission of derived phenotypes for molecular genetic studies of substance use disorders
    Stephen V Faraone
    Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams St, Syracuse, NY 13210, USA
    Drug Alcohol Depend 92:100-7. 2008
    ..001; cognitive impairment: OR=1.33, p=0.04); in offspring, baseline psychopathology predicted SUD at follow-up assessments (OR=1.55, p=0.01). Results suggest that these candidate SUD phenotypes may be useful for genetic studies of SUD...
  28. ncbi Association of bipolar and substance use disorders in parents of adolescents with bipolar disorder
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, and Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 62:129-34. 2007
    ..We have previously shown that juvenile bipolar disorder (BPD) is a risk for substance use disorders (SUD). Here we examine the expression of both disorders in families of youth with BPD to evaluate the familial risk mechanism...
  29. ncbi Substance use among ADHD adults: implications of late onset and subthreshold diagnoses
    Stephen V Faraone
    Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York 13210, USA
    Am J Addict 16:24-32; quiz 33-4. 2007
    ..In contrast, subthreshold ADHD seems to be a milder form of the disorder, or perhaps a heterogeneous group of true ADHD cases and false positives...
  30. ncbi A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults
    Stephen V Faraone
    Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Psychol Med 37:1743-52. 2007
    ....
  31. ncbi Attention deficit hyperactivity disorder and substance use disorders
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 163:2059-63. 2006
  32. ncbi Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD
    John Polzer
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Biol Psychiatry 61:713-9. 2007
    ..We systematically examined potential aggression/hostility-related events in a meta-analysis of acute clinical trials of atomoxetine for attention-deficit/hyperactivity disorder (ADHD)...
  33. ncbi Combination pharmacotherapy for adult ADHD
    Lenard A Adler
    Faculty Practice Offices, NYU School of Medicine, 530 First Avenue, New York, NY 10016, USA
    Curr Psychiatry Rep 8:409-15. 2006
    ..Adjunct treatment of mirtazapine to stimulant medications reduced associated insomnia. These data support previous research that validates the use of combination pharmacotherapy for adults with ADHD...
  34. ncbi Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Massachusetts General Hospital, Department of Psychiatry, Boston, Massachusetts, USA
    J Pediatr 149:112-9. 2006
    ..To determine the efficacy and safety of atomoxetine in adolescent subjects treated for attention-deficit/hyperactivity disorder (ADHD) for up to 2 years...
  35. ncbi An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 67:696-702. 2006
    ....
  36. ncbi When ADHD and substance use disorders intersect: relationship and treatment implications
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Curr Psychiatry Rep 9:408-14. 2007
    ..In contrast, medication treatment alone of adults with ADHD and current SUD is inadequate for both ADHD and SUD. Stimulant diversion continues to be of concern, particularly in older adolescents and young adults...
  37. ncbi Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders
    Joseph Biederman
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, 55 Fruit St, Warren 705, Boston, MA 02114, USA
    Am J Psychiatry 165:107-15. 2008
    ..A robust and bidirectional comorbidity between attention deficit hyperactivity disorder (ADHD) and psychoactive substance use disorder (alcohol or drug abuse or dependence) has been consistently reported in the extant literature...
  38. ncbi Pharmacotherapy of ADHD in adults
    Timothy E Wilens
    Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
    CNS Spectr 13:11-3. 2008
  39. ncbi Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders
    Timothy E Wilens
    Massachusetts General Hospital, 55 Fruit Street, YAW 6900, Boston, MA 02114, USA
    Drug Alcohol Depend 96:145-54. 2008
    ..The study aim was to determine if atomoxetine was superior to placebo in improving ADHD and alcohol use in recently abstinent adults with ADHD and comorbid alcohol use disorder...
  40. ncbi Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents
    Timothy E Wilens
    Pediatric Psychopharmacology Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Arch Pediatr Adolesc Med 162:916-21. 2008
    ..To examine the effects of early stimulant treatment on subsequent risk for cigarette smoking and substance use disorders (SUDs) in adolescents with attention-deficit/hyperactivity disorder (ADHD)...
  41. ncbi Further evidence of an association between adolescent bipolar disorder with smoking and substance use disorders: a controlled study
    Timothy E Wilens
    Massachusetts General Hospital, Pediatric Psychopharmacology Unit, Boston, MA 02114, USA
    Drug Alcohol Depend 95:188-98. 2008
    ..Clinicians should carefully screen adolescents with bipolar disorder for substance and cigarette use...
  42. ncbi Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study
    Joseph Biederman
    Research Program in Pediatric Psychopharmacology and Adult ADHD, Department of Psychiatry, Massachusetts General Hospital, Boston 02114, USA biederman helix mgh harvard edu
    Am J Psychiatry 165:597-603. 2008
    ..The authors examined the association between stimulant treatment in childhood and adolescence and subsequent substance use disorders (alcohol, drug, and nicotine) into the young adult years...
  43. ncbi Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion
    Stephen V Faraone
    Department of Psychiatry and the Department of Behavioral Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    J Clin Psychiatry 68:15-22. 2007
    ..Misuse and diversion of prescribed stimulants occur among a minority of ADHD patients, especially those with conduct or substance use disorders. Long-acting stimulants may be less likely to be misused or diverted...
  44. ncbi Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Am Acad Child Adolesc Psychiatry 47:700-8. 2008
    ..The objectives of this study were to determine the efficacy, duration of action, and safety of methylphenidate transdermal system worn for variable times by children (ages 6-12) diagnosed with ADHD...
  45. ncbi ADHD: prevalence, diagnosis, and issues of comorbidity
    Timothy E Wilens
    Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
    CNS Spectr 12:1-5. 2007
  46. ncbi The nature of the relationship between attention-deficit/hyperactivity disorder and substance use
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Department of Psychiatry, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:4-8. 2007
    ..Individuals with SUD and ADHD have a more severe and complicated course of SUD. Pharmacotherapeutic treatment of ADHD in children reduces the risk for later cigarette smoking and SUD in adulthood...
  47. ncbi Supraventricular tachycardia in an adolescent with attention-deficit/hyperactivity disorder (ADHD)
    Paul G Hammerness
    J Am Acad Child Adolesc Psychiatry 47:219-20. 2008
  48. ncbi Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Am Acad Child Adolesc Psychiatry 47:21-31. 2008
    ..The purpose of this systematic review of the literature is to evaluate the extent and characteristics of stimulant misuse and diversion in attention-deficit/hyperactivity disorder (ADHD) and non-ADHD individuals...
  49. ncbi A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents
    Karen Dineen Wagner
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77755 0188, USA
    Am J Psychiatry 163:1179-86. 2006
    ..This multicenter trial examined the efficacy and safety of oxcarbazepine in the treatment of bipolar disorder in children and adolescents...
  50. ncbi Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder
    James J McGough
    Semel Institute for Neuroscience and Human Behavior, and David Geffen School of Medicine at UCLA, 300 UCLA Medical Plaza, Los Angeles, CA 90095, USA
    J Child Adolesc Psychopharmacol 16:351-6. 2006
    ..Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events. The incidence of adverse events was not related to dose. OROS MPH was safe and well tolerated at doses up to 72 mg/day...
  51. ncbi Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:253-9. 2005
    ..To evaluate the effects of medications used in the treatment of adults with attention-deficit/hyperactivity disorder (ADHD) on blood pressure and pulse...
  52. ncbi A clinical perspective of attention-deficit/hyperactivity disorder into adulthood
    Timothy E Wilens
    Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Psychiatry 65:1301-13. 2004
    ..Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder that affects all age groups. Recent data on the clinical presentation, comorbidity, neurobiology, and treatment are reviewed...
  53. ncbi Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children
    Joseph Biederman
    Pediatric Psychopharmacology Unit, Psychiatry Department, Massachusetts General Hospital, Boston, MA 02114, USA
    J Consult Clin Psychol 72:757-66. 2004
    ..Children and adolescents with ADHD and EFDs were found to be at high risk for significant impairments in academic functioning. These results support screening children with ADHD for EFDs to prevent academic failure...
  54. ncbi Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination
    Joseph Gonzalez-Heydrich
    Children s Hospital, 300 Longwood Avenue, Boston, MA 02115, USA
    J Am Acad Child Adolesc Psychiatry 42:1227-33. 2003
    ..To evaluate hepatic enzyme elevations during treatment with olanzapine, divalproex, and their combination...
  55. ncbi Does the medicating ADHD increase or decrease the risk for later substance abuse?
    Timothy E Wilens
    Rev Bras Psiquiatr 25:127-8. 2003
  56. ncbi Current concepts in the validity, diagnosis and treatment of paediatric bipolar disorder
    Joseph Biederman
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02114 3139, USA
    Int J Neuropsychopharmacol 6:293-300. 2003
    ..The goal of this article is to review our work and the extant literature within this framework to describe the evidence supporting bipolar disorder in children as a valid clinical diagnosis...
  57. ncbi An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Biol Psychiatry 54:9-16. 2003
    ..Further controlled trials are warranted...
  58. ncbi Can adults with attention-deficit/hyperactivity disorder be distinguished from those with comorbid bipolar disorder? Findings from a sample of clinically referred adults
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Biol Psychiatry 54:1-8. 2003
    ..We now evaluate the clinical characteristics of referred adults with (n = 24) and without BPD (n = 27)...
  59. ncbi Novel treatments for attention-deficit/hyperactivity disorder in children
    Thomas J Spencer
    Pediatric Psychopharmacology Unit, Psychiatry Service, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 63:16-22. 2002
    ....
  60. ncbi Overview and neurobiology of attention-deficit/hyperactivity disorder
    Thomas J Spencer
    Pediatric Psychopharmacology Unit, Psychiatry Service, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 63:3-9. 2002
    ..Therefore, the treatment characteristics of newer, more selective treatments such as atomoxetine should continue to be explored in ADHD...
  61. ncbi Temporal association between childhood psychopathology and substance use disorders: findings from a sample of adults with opioid or alcohol dependency
    Amy L Hahesy
    Pediatric and Adult Psychopharmacology Clinic, Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 15 Parkman Street, ACC 725, Boston, MA 02114, USA
    Psychiatry Res 109:245-53. 2002
    ..These findings further highlight the importance of targeting antecedent disorders for preventive and early intervention programs aimed at reducing the risk for SUD...
  62. ncbi Influence of parental SUD and ADHD on ADHD in their offspring: preliminary results from a pilot-controlled family study
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Am J Addict 14:179-87. 2005
    ..Replication studies clarifying the nature and strength of the association are necessary...
  63. ncbi Is cigarette smoking a gateway to alcohol and illicit drug use disorders? A study of youths with and without attention deficit hyperactivity disorder
    Joseph Biederman
    Department of Psychiatry, Harvard Medical School, USA
    Biol Psychiatry 59:258-64. 2006
    ....
  64. ncbi Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study
    Thomas J Spencer
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Ther 28:266-79. 2006
    ..The ability to recognize and diagnose attention-deficit/hyperactivity disorder (ADHD) has increased in recent years. The persistence of ADHD symptoms puts adolescents with ADHD at risk for long-term adverse psychosocial outcomes...
  65. ncbi Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Am Acad Child Adolesc Psychiatry 45:408-14. 2006
    ..As part of a 10-year longitudinal study of youths with ADHD, the authors evaluated medication diversion or misuse at the last follow-up period...
  66. ncbi ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study
    Timothy E Wilens
    Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Psychiatry 59:1065-70. 2006
    ..This pilot study was designed to evaluate ABT-089, a neuronal nicotinic receptor partial agonist, as treatment for adult attention-deficit/hyperactivity disorder (ADHD)...
  67. ncbi Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study
    Joseph Biederman
    Pediatric Psychopharmacology Unit of the Psychiatry Department, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychol Med 36:167-79. 2006
    ..Our objective was to estimate the lifetime prevalence of psychopathology in a sample of youth with and without attention deficit hyperactivity disorder (ADHD) through young adulthood using contemporaneous diagnostic and analytic techniques...
  68. ncbi Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, YAW 6 6A, 32 Fruit Street, Boston, MA 02114, USA
    Arch Pediatr Adolesc Med 160:82-90. 2006
    ..Despite the persistence of attention-deficit/hyperactivity disorder (ADHD) into adolescence, little is known about the efficacy and tolerability of stimulant medications in this age group...
  69. ncbi An open trial of adjunctive donepezil in attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, YAW 6A, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Child Adolesc Psychopharmacol 15:947-55. 2005
    ..We sought to determine if donepezil, used adjunctively to stimulant medication, would improve residual symptoms of ADHD and EF deficits...
  70. ncbi Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD
    Richard H Weisler
    Duke University Medical Center, University of North Carilina, Chapel Hill, Raleigh 27609, USA
    CNS Spectr 10:35-43. 2005
    ..To assess long-term cardiovascular effects of mixed amphetamine salts extended release (MAS XR) in adults with attention-deficit/hyperactivity disorder (ADHD) combined subtype...
  71. ncbi Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders
    Ramon Solhkhah
    Pediatric Psychopharmacology Unit, Division of Child and Adolescent Psychiatry, Massachusetts General Hospital and Harvard Medical School, USA
    J Child Adolesc Psychopharmacol 15:777-86. 2005
    ..The ratings were completed at baseline, at month 3, and at the 6-month endpoint. Bupropion SR was initiated at 100 mg once-daily and titrated naturalistically to a maximum dose of 400 mg/day...
  72. ncbi Neuropsychological functioning in youth with bipolar disorder
    Alysa E Doyle
    Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
    Biol Psychiatry 58:540-8. 2005
    ..We compared neuropsychological and academic functioning of youth with and without DSM-IV BPD, controlling for effects of comorbid ADHD...
  73. ncbi Characteristics of adults with attention deficit hyperactivity disorder plus substance use disorder: the role of psychiatric comorbidity
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA, USA
    Am J Addict 14:319-27. 2005
    ..Clinicians need to be attentive to other psychiatric disorders that may occur in the large group of adults with ADHD + SUD...
  74. ncbi Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children
    Robert L Findling
    University Hospitals of Cleveland, Cleveland, Ohio 44106 5080, USA
    J Pediatr 147:348-54. 2005
    ....
  75. ncbi Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic
    Joseph Biederman
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 159:36-42. 2002
    ..In this study the authors systematically examined the impact of gender on the clinical features of ADHD in a group of children referred to a clinic...